Surface modification of lipid-based nanocarriers for cancer cellspecific drug targeting
활용도 Analysis
논문 Analysis
연구자 Analysis
저자
김창현
이상곤
강명주
이상길
최영욱
제어번호
103673701
학술지명
Journal of Pharmaceutical Investigation
권호사항
Vol.
47
No.
3
[
2017
]
발행처
한국약제학회
발행처 URL
http://www.kspst.or.kr
자료유형
학술저널
수록면
203-227
(
25쪽)
언어
English
출판년도
2017
등재정보
KCI등재
판매처
'
Surface modification of lipid-based nanocarriers for cancer cellspecific drug targeting' 의 참고문헌
pH-sensitive mPEG-Hz-cholesterol conjugates as a liposome delivery system
Chen D
J Bioact Compat Polym 25 527-542
[2010]
pH-responsive biodegradable assemblies containing tunable phenyl-substituted vinyl ethers for use as efficient gene delivery vehicles
Kim HK
ACS Appl Mater Interfaces 5 5648-5658
[2013]
Which one performs better for targeted lung cancer combination therapy: pre-or post-bombesin-decorated nanostructured lipid carriers?
Du J
Drug Deliv 23 1799-1809
[2016]
Uptake and intracellular processing of targeted and nontargeted liposomes by Rat Kupffer Cells in vivo and in vitro
Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer
Zagar TM
Int J Hyperthermia 30 285-294
[2014]
Tumor-targeting peptides from combinatorial libraries
Liu R
Adv Drug Deliv Rev -
[2016]
Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas
Yang ZZ
Biomaterials 35 5226-5239
[2014]
Tumor targeting of functionalized lipid nanoparticles:assessment by in vivo fluorescence imaging
Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody
Liu D
Mol Pharm 8 2291-2301
[2011]
Tumor microenvironment and intracellular signal-activated nanomaterials for anticancer drug delivery
Mo R
Mater Today 19 274-283
[2016]
Transferrinmodified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin
Han Y
Int J Nanomedicine 9 4107-4116
[2014]
Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots
Muthu MS
Biomaterials 33 3494-3501
[2012]
The use of cell-penetrating peptides for drug delivery
The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes
Gao J
Biomaterials 32 3459-3470
[2011]
The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma
Iyer AK
Biomaterials 32 2605-2613
[2011]
The dawning era of polymer therapeutics
Duncan R
Nat Rev Drug Discov 2 347-360
[2003]
The accelerated clearance on repeated injection of pegylated liposomes in rats: laboratory and histopathological study
Ishida T
Cell Mol Biol Lett 7 286-286
[2002]
The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo
Maeda H
Adv Drug Deliv Rev 65 71-79
[2013]
Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers
Targeting tumor-associated endothelial cells:anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth
Wicki A
Clin Cancer Res 18 454-464
[2012]
Targeting receptor-mediated endocytotic pathways with nanoparticles:rationale and advances
Xu S
Adv Drug Deliv Rev 65 121-138
[2013]
Targeting etoposide to acute myelogenous leukemia cells using nanostructured lipid carriers coated with transferrin
Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering
Guo Z
Biomaterials 35 6106-6117
[2014]
Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide
Garg A
Int J Pharm 366 201-210
[2009]
Targeted therapy using nanotechnology:focus on cancer
Sanna V
Int J Nanomedicine 9 467-483
[2014]
Targeted therapies for cancer 2004
Ross JS
Am J Clin Pathol 122 598-609
[2004]
Targeted paclitaxel delivery to tumors using cleavable PEG-conjugated solid lipid nanoparticles
Zheng J
Pharm Res 31 2220-2233
[2014]
Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA
Shao Z
Int J Nanomedicine 10 1223-1233
[2015]
Targeted drug delivery via the folate receptor
Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma
Yuan M
Drug Deliv 23 1171-1183
[2016]
Targeted delivery of etoposide to cancer cells by folate-modified nanostructured lipid drug delivery system
Zhang S
Drug Deliv 23 1838-1845
[2016]
Targeted delivery of doxorubicin using stealth liposomes modified with transferrin
Li X
Int J Pharm 373 116-123
[2009]
Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly (ethylene glycol) comodified liposomal delivery system via systemic administration
Kuai R
Mol Pharm 8 2151-2161
[2011]
Targeted anticancer therapy: overexpressed receptors and nanotechnology
Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEGlipid
Synthesis, characterization and radiolabeling of folic acid modified nanostructured lipid carriers as a contrast agent and drug delivery system
Ucar E
Appl Radiat Isot 119 72-79
[2017]
Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome
Surface-modification of RIPL peptide-conjugated liposomes to achieve steric stabilization and pH sensitivity
Kwon YH
J Nanosci Nanotechnol 17 1008-1017
[2017]
Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity
Biswas S
Eur J Pharm Biopharm 84 517-525
[2013]
Studies on PEG-modified SLNs loading vinorelbine bitartrate (I): preparation and evaluation in vitro
Wan F
Int J Pharm 359 104-110
[2008]
Strategies for the intracellular delivery of nanoparticles
Chou LY
Chem Soc Rev 40 233-245
[2011]
Stimuli-responsive nanoparticles for targeting the tumor microenvironment
Du J
J Control Release 219 205-214
[2015]
Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting
Li SD
J Control Release 145 178-181
[2010]
Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential
Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes
Dai W
Pharm Res 29 2902-2911
[2012]
Solid lipid nanoparticles: production, characterization and applications
Mehnert W
Adv Drug Deliv Rev 47 165-196
[2001]
Solid lipid nanoparticles for parenteral drug delivery
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations
Müller RH
Adv Drug Deliv Rev 54 S131-S155
[2002]
Sheddable coatings for long-circulating nanoparticles
Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin
Jiang J
Eur J Pharm Biopharm 76 170-178
[2010]
Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells
Repeated administration of hyaluronic acid coated liposomes with improved pharmacokinetics and reduced immune response
Zhang Q
Mol Pharm 13 1800-1808
[2016]
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment
Hobbs SK
Proc Natl Acad Sci U S A 95 4607-4612
[1998]
Reductiontriggered delivery using nucleoside-lipid based carriers possessing a cleavable PEG coating
Oumzil K
J Control Release 151 123-130
[2011]
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan
Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier
Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma
Gill PS
J Clin Oncol 14 2353-2364
[1996]
RNAi-mediated gene knockdown and antiangiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system
Sakurai Y
J Control Release 173 110-118
[2014]
RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated liposomes for enhanced intracellular drug delivery to hepsin-expressing cancer cells
Kang MH
Eur J Pharm Biopharm 87 489-499
[2014]
RGDmodified pH-sensitive liposomes for docetaxel tumor targeting
Chang M
Colloids Surf B Biointerf 129 175-182
[2015]
RGDconjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells
Shan D
Drug Deliv Transl Res 5 15-26
[2015]
Protein resistance of PEG-functionalized dendronized surfaces: effect of PEG molecular weight and dendron generation
Prolongation of residence time of liposome by surface-modification with mixture of hydrophilic polymers
Principles in the design of ligand-targeted cancer therapeutics and imaging agents
Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel
Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems
Üner M
Pharmazie 61 375-386
[2006]
Preparation and pharmacokinetics of docetaxel based on nanostructured lipid carriers
Li X
J Pharm Pharmacol 61 1485-1492
[2009]
Potential use of drug carried-liposomes for cancer therapy via direct intratumoral injection
Bao A
Int J Pharm 316 162-169
[2006]
Phase I study of liposome entrapped paclitaxel (LEP-ETU) in patients with advanced cancer
Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101)
Pharmacokinetics and tissue distribution of idarubicinloaded solid lipid nanoparticles after duodenal administration to rats
Zara GP
J Pharm Sci 91 1324-1333
[2002]
Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent
Accardo A
Int J Nanomedicine 7 2007-2017
[2012]
Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo
Cai L
Int J Nanomedicine 7 4499-4510
[2012]
Pegylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides
Remaut K
J Control Release 117 256-266
[2007]
Past and future perspectives of synthetic peptide libraries
Marasco D
Curr Protein Pept Sci 9 447-467
[2008]
Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting
Liu Y
Biomaterials 35 4835-4847
[2014]
PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles
Mishra S
Eur J Cell Biol 83 97-111
[2004]
PEGylation and its impact on the design of new protein-based medicines
Ginn C
Future Med Chem 6 1829-1846
[2014]
PEGylated nanostructured lipid carriers loaded with 10- hydroxycamptothecin: an efficient carrier with enhanced anti- tumour effects against lung cancer
Zhang X
J Pharm Pharmacol 60 1077-1087
[2008]
PEGylated nanomedicines:recent progress and remaining concerns
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma
Octaargininemodified multifunctional envelope-type nano device for siRNA
Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer
Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells
Chen Y
Mol Pharm 6 696-705
[2009]
Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy
Song S
Drug Deliv 23 1404-1408
[2016]
Novel PEG-matrix metalloproteinase-2 cleavable peptidelipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting
Terada T
J Control Release 111 333-342
[2006]
Non-stealth and stealth solid lipid nanoparticles (SLN)carrying doxorubicin: pharmacokinetics and tissue distribution after iv administration to rats
Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery
Sinha R
Mol Cancer Ther 5 1909-1917
[2006]
Nanostructured lipid matrices for improved microencapsulation of drugs
Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies
Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA
Nanostructured lipid carrier (NLC) a modern approach for topical delivery: a review
Patel DK
World J Pharm Pharma Sci 2 921-938
[2013]
Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake
Nanoparticle and targeted systems for cancer therapy
Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications
Wicki A
J Control Release 200 138-157
[2015]
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
Multifunctional tandem peptide modified paclitaxel-loaded liposomes for the treatment of vasculogenic mimicry and cancer stem cells in malignant glioma
Liu Y
ACS Appl Mater Interfaces 7 16792-16801
[2015]
Multifunctional and stimuli-sensitive pharmaceutical nanocarriers
Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity
Koren E
J Control Release 160 264-273
[2012]
Multi-functional vesicles for cancer therapy: the ultimate magic bullet
Tavano L
Colloids Surf B Biointerf 147 161-171
[2016]
Monoclonal antibody-targeted, temperature-sensitive liposomes: in vivo tumor chemotherapeutics in combination with mild hyperthermia
Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent
Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice
Gupta B
Cancer Immunol Immunother 56 1215-1223
[2007]
Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting
Zhu L
ACS Nano 6 3491-3498
[2012]
Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors
Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug
Jain A
J Control Release 148 359-367
[2010]
MMP-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer
Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing
Gao J
Biomaterials 31 2655-2664
[2010]
Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes
He Y
Int J Nanomedicine 5 697-705
[2010]
Long circulating poly (ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors
Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals
Qin Y
Int J Pharm 420 304-312
[2011]
Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery
Qin Y
Int J Pharm 419 85-95
[2011]
Lipid nanoparticles for parenteral delivery of actives
Joshi MD
Eur J Pharm Biopharm 71 161-172
[2009]
Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products
Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery
Chen H
Eur J Pharm Sci 40 94-102
[2010]
Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas
Chen H
Eur J Pharm Sci 44 164-173
[2011]
Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation
Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2
Investigation of enzyme-sensitive lipid nanoparticles for delivery of siRNA to blood-brain barrier and glioma cells
Bruun J
Int J Nanomedicine 10 5995-6008
[2015]
Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects
Increased tumor targeted delivery using a multistage liposome system functionalized with RGD TAT and cleavable PEG
Mei L
Int J Pharm 468 26-38
[2014]
Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrinmodified liposomes
In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel
Chen DB
Chem Pharm Bull 49 1444-1447
[2001]
In vitro and in vivo evaluation of folate receptor-targeting amphiphilic copolymer modified liposomes loaded with docetaxel
Li X
Int J Nanomedicine 6 1167-1184
[2011]
In vitro and in vivo antitumor effects of folate-targeted ursolic acid Stealth liposome
Yang G
J Agric Food Chem 62 2207-2215
[2014]
Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas
Amin M
Int J Pharm 458 324-333
[2013]
Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide
Chen X
J Controll Release 145 17-25
[2010]
Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives
Üner M
Int J Nanomedicine 2 289-300
[2007]
Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma
Hypoxia targeted siRNA delivery
Perche F
Angew Chem Int Ed Engl 53 3362-3366
[2014]
Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy
Cai D
Biomaterials 35 2283-2294
[2014]
Hyaluronic acid-coated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cells
Tran TH
Carbohydr Polym 114 407-415
[2014]
Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer
Yang XY
Cancer Lett 334 338-345
[2013]
Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation
Ravar F
J Control Release 229 10-22
[2016]
Hyaluronic acid-coated liposomes for active targeting of gemcitabine
Arpicco S
Eur J Pharm Biopharm 85 373-380
[2013]
Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine
Hyaluronic acid (hyaluronan): a review
Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells
High tumor penetration of paclitaxel loaded pH sensitive cleavable liposomes by depletion of tumor collagen I in breast cancer
Zhang L
ACS Appl Mater Interfaces 7 9691-9701
[2015]
Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage
Shmeeda H
J Control Release 136 155-160
[2009]
Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin
Wei M
Eur J Pharm Sci 46 131-141
[2012]
Glucosamine derivative modified nanostructured lipid carriers for targeted tumor delivery
Chen J
J Mater Chem 22 5770-5783
[2012]
Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin
Jain A
Colloids Surf B Biointerf 134 47-58
[2015]
GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation
Cheng L
Int J Nanomedicine 9 921-935
[2014]
Folic acidtethered Pep-1 peptide-conjugated liposomal nanocarrier for enhanced intracellular drug delivery to cancer cells: conformational characterization and in vitro cellular uptake evaluation
Kang MJ
Int J Nanomedicine 8 1155-1165
[2013]
Folate-targeted chemotherapy
Leamon CP
Adv Drug Deliv Rev 56 8 1127-1141
[2004]
Folate-mediated solid–liquid lipid nanoparticles for paclitaxel-coated poly(ethylene glycol)
Wu L
Drug Dev Ind Pharm 36 439-448
[2010]
Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting
Ye P
Int J Nanomedicine 9 2167-2178
[2014]
Folate and TAT peptide co-modified liposomes exhibit receptor-dependent highly efficient intracellular transport of payload in vitro and in vivo
Zhu Y
Pharm Res 31 3289-3330
[2014]
Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery
Exploiting tumour hypoxia in cancer treatment
Brown JM
Nat Rev Cancer 4 437-447
[2004]
Evaluating cytotoxicity of hyaluronate targeted solid lipid nanoparticles of etoposide on SK-OV-3 cells
Etoposide-incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling, and biodistribution studies
Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy
Enzymeresponsive liposomes modified adenoviral vectors for enhanced tumor cell transduction and reduced immunogenicity
Wan Y
Biomaterials 34 3020-3030
[2013]
Enzyme-responsive nanoparticles for drug release and diagnostics
Enzyme-responsive nanomaterials for controlled drug delivery
Hu Q
Nanoscale 6 12273-12286
[2014]
Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy
Qu CY
Int J Nanomedicine 10 3911-3920
[2015]
Efficacy of interleukin-13 receptor–targeted liposomal doxorubicin in the intracranial brain tumor model
Efficacy of dual-functional liposomes containing paclitaxel for treatment of lung cancer
Wang RH
Oncol Rep 33 783-791
[2015]
Effects of a novel pH-sensitive liposome with cleavable esterase-catalyzed and pH-responsive double smart mPEG lipid derivative on ABC phenomenon
Chen D
Int J Nanomedicine 6 2053-2061
[2011]
Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells
Effect of octreotide–polyethylene glycol (100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine
Su Z
Mol Pharm 8 1641-1651
[2011]
Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization
Su Z
Int J Pharm 447 281-292
[2013]
EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma
Gao J
Biomaterials 33 270-282
[2012]
Dysregulated pH: a perfect storm for cancer progression
Webb BA
Nat Rev Cancer 11 671-677
[2011]
Dualfunctional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells
Zhang X
Biomaterials 33 7103-7114
[2012]
Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery
Kibria G
J Control Release 153 141-148
[2011]
Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress
Lammers T
J Control Release 161 175-187
[2012]
Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice
Hong RL
Clin Cancer Res 5 3645-3652
[1999]
Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid
Design of multifunctional liposomal nanocarriers for folate receptor-specific intracellular drug delivery
Kang MH
Mol Pharm 12 4200-4213
[2015]
Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells
Delivery of siRNA using lipid nanoparticles modified with cell penetrating peptide
Li Y
ACS Appl Mater Interfaces 8 26613-26621
[2016]
Decaarginine-PEG-liposome enhanced transfection efficiency and function of arginine length and PEG
Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery
Coating solid lipid nanoparticles with hyaluronic acid enhances antitumor activity against melanoma stem-like cells
Shen H
Theranostics 5 755-771
[2015]
Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer
Xu X
Asian Pac J Cancer Prev 14 2591-2594
[2013]
Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker
Hou C
Nucl Med Biol 33 203-209
[2006]
Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronangrafted liposomes
Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer
Cell-penetrating peptides—mechanisms of cellular uptake and generation of delivery systems
Cell-penetrating peptides: design, synthesis, and applications
Cell penetrating peptides as an innovative approach for drug delivery; then, present and the future
Santosh Bashyal
Journal of Pharmaceutical Investigation 46 3 205-220
[2016]
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology
Cancer chemotherapy with lipid-based nanocarriers
Liu D
Crit Rev Ther Drug Carrier Syst 27 371-417
[2010]
CD44antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma
Wang L
Biomaterials 33 5107-5114
[2012]
Antitumor activity of tumor-targeted RNA replicase-based plasmid that expresses interleukin-2 in a murine melanoma model
Antitumor activity of tripterine via cell-penetrating peptide-coated nanostructured lipid carriers in a prostate cancer model
Yuan L
Int J Nanomedicine 8 4339-4350
[2013]
Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice
Kim IY
J Control Release 140 55-60
[2009]
Antibody-mediated targeting of the transferrin receptor in cancer cells
Luria-Pérez R
Boletín Médico del Hospital Infantil de México 73 372-379
[2016]
Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells
An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor
Chono S
J Control Release 131 64-69
[2008]
An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery
Ding Y
Int J Nanomedicine 10 6199-6214
[2015]
Advances in investigations on the mechanism of cancer multidrug resistance and the liposomes-based treatment strategy
Fan Zeng
Journal of Pharmaceutical Investigation 44 7 493-504
[2014]
Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes
Dams ET
J Pharmacol Exp Ther 292 1071-1079
[2000]
A systematic in vitro investigation on poly-arginine modified nanostructured lipid carrier: pharmaceutical characteristics, cellular uptake, mechanisms and cytotoxicity
Sun M
Asian J Pharm Sci 12 51-58
[2016]
A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)
Awada A
Ann Oncol 25 824-831
[2014]
A phase I study of doxorubicin-loaded anti-EGFR immunoliposomes in patients with advanced solid tumors
Mamot C
J Clin Oncol 29 3029-3029
[2011]
A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin
A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models
Zhang J
Mol Pharm 7 1159-1168
[2010]
A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy
Paliwal SR
Curr Cancer Drug Targets 10 343-353
[2010]
A novel anti-VEGF165 monoclonal antibody-conjugated liposomal nanocarrier system: physical characterization and cellular uptake evaluation in vitro and in vivo
Shi C
Biomed Pharmacother 69 191-200
[2015]
A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
Ko AH
Br J Cancer 109 920-925
[2013]
A detachable coating of cholesterol-anchored PEG improves tumor targeting of cell-penetrating peptide-modified liposomes
Tang J
Acta Pharm Sin B 4 67-73
[2014]
'
Surface modification of lipid-based nanocarriers for cancer cellspecific drug targeting'
의 유사주제(
) 논문